TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
Stocks · News reference
Ginkgo Bioworks To Provide Autonomous Lab Access To NSF X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5B Science Program; To Provide Cloud Lab Time And Remote Access For NSF X-Labs Teams; To Offer Protein Testing Services To NSF X-Labs Teams
Ginkgo Bioworks (NYSE:DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was announced today by
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks offers remote autonomous lab access to NSF X-Labs and integrates Araceli imaging into its Boston platform.
Ginkgo Bioworks shares are trading higher after the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program.